Related Experiment Video
Updated: Jun 25, 2026
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Interferon-a sensitivity in melanoma cells: detection of potential response marker genes
Ulrich Certa1, Monika Seiler, Elisabetta Padovan
1F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, Basel, Switzerland.
Abstract:
Interferon alpha (IFN-alpha) represents an adjuvant therapy of proven effectiveness in increasing disease-free interval and survival in subgroups of melanoma patients. Since high doses of cytokine are required, the treatment is often accompanied by toxic side effects. In addition, naturally occurring insensitivity to IFN-alpha may hamper its therapeutic efficacy. Clinical, molecular or immunological markers enabling the selection of potential responders have not so far been identified. To explore the molecular basis of IFN-alpha responsiveness, we analyzed the expression pattern of about 7000 genes in IFN-alpha-sensitive and IFN-alpha-resistant cell lines using high-density oligonucleotide arrays. Melanoma cell lines were screened for their sensitivity to proliferation inhibition and HLA class I induction by IFN-alpha by standard 3H-thymidine incorporation and flow cytometry. Total cellular RNA from four sensitive and two resistant cell lines was extracted, reverse-transcribed and hybridized to high-density oligonucleotide arrays. The comparative analysis of gene expression in either set of cell lines allowed the identification of four genes (RCCl, IFI16, hox2 and h19) preferentially transcribed in sensitive cells and two (SHB and PKC-zeta) preferentially expressed in resistant cells. These data may provide a useful basis for the development of diagnostic tools to select potential IFN-alpha responders as eligible for treatment, while avoiding unnecessary toxicity to nonresponders.
Insights
Interferon alpha (IFN-alpha) therapy shows promise for melanoma but has side effects and variable effectiveness. This study identified specific genes linked to IFN-alpha sensitivity, potentially aiding treatment selection.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interferon alpha (IFN-alpha) is an effective adjuvant therapy for melanoma, improving disease-free survival in select patients.
- High-dose IFN-alpha treatment often causes toxic side effects, and natural insensitivity can limit its efficacy.
- Currently, no reliable clinical, molecular, or immunological markers exist to identify patients who will respond to IFN-alpha therapy.
Purpose of the Study:
- To investigate the molecular basis of IFN-alpha responsiveness in melanoma.
- To identify gene expression patterns differentiating IFN-alpha-sensitive from IFN-alpha-resistant melanoma cell lines.
Main Methods:
- Utilized high-density oligonucleotide arrays to analyze gene expression patterns in approximately 7000 genes.
- Screened melanoma cell lines for sensitivity to IFN-alpha-induced proliferation inhibition and HLA class I induction.
- Performed comparative gene expression analysis on RNA extracted from four sensitive and two resistant melanoma cell lines.
Main Results:
- Identified four genes (RCCl, IFI16, hox2, h19) preferentially transcribed in IFN-alpha-sensitive melanoma cell lines.
- Identified two genes (SHB, PKC-zeta) preferentially expressed in IFN-alpha-resistant melanoma cell lines.
- Gene expression profiles correlate with IFN-alpha sensitivity in melanoma cells.
Conclusions:
- The identified genes may serve as biomarkers for predicting IFN-alpha response in melanoma patients.
- These findings could facilitate the development of diagnostic tools for patient selection.
- This approach aims to optimize IFN-alpha therapy by targeting responders and avoiding toxicity in non-responders.
